Real-Time Real Talk | Continuous Glucose Monitoring (CGM) Education for Healthcare Providers

Why did Dexcom move to a 15-day sensor? Because they listened. In this episode of Real Time Real Talk, host Cher Pastore talks with Grant Owzinski, VP of Product Management at Dexcom, about the research, design, and real-world impact behind the new G7 15-Day. From longer wear and fewer sensor changes to photo logging with AI, Grant explains how Dexcom continues to evolve to meet the needs of patients and healthcare professionals alike — making life with diabetes simpler, smarter, and more connected. ---- Disclaimer: This podcast is not approved for CME credit. Every diabetes treatment plan is different, individual results may vary – nothing you hear on this podcast should be considered medical advice. All claims are supported by clinical evidence referenced in the show notes. For clinical study results, please refer to the Dexcom G7 User Guide. For product-related questions, please refer to the instructions for use. For complete safety information, go to dexcom.com/safety-information. Fingersticks required for diabetes treatment decisions if symptoms or expectations do not match readings. Dexcom G7 can complete warmup within 30 minutes, whereas other CGM brands require up to an hour or longer. Smart devices are sold separately. For a list of compatible smart devices, visit: dexcom.com/compatibility. “Dexcom" refers to the Dexcom CGM. Compatible smartphone is required to pair a new Dexcom G7 sensor with a compatible Apple Watch. To use Share/Follow the smartphone must be within 33 feet of the Dexcom G7. The Dexcom G7 Continuous Glucose Monitoring System (Dexcom G7 System) is a real time, continuous glucose monitoring device indicated for the management of diabetes in persons aged 2 years and older. Dexcom G7 has no limitations for use in pregnancy. G7 15 Day is only for adults 18+. This guest is a paid spokesperson for Dexcom. Brief Safety Statement:                                                                                                        Failure to use the Dexcom Continuous Glucose Monitoring System and its components according to the instructions for use provided with your device and available at https://www.dexcom.com/safety-information and to properly consider all indications, contraindications, warnings, precautions, and cautions in those instructions for use may result in you missing a severe hypoglycemia (low blood glucose) or hyperglycemia (high blood glucose) occurrence and/or making a treatment decision that may result in injury. If your glucose alerts and readings from the Dexcom CGM do not match symptoms, use a blood glucose meter to make diabetes treatment decisions. Seek medical advice and attention when appropriate, including for any medical emergency. Dexcom, Dexcom Follow, Dexcom Clarity, and Dexcom Share are registered trademarks of Dexcom, Inc. in the U.S., and may be registered in other countries. STELO IMPORTANT INFORMATION: Consult your healthcare provider before making any medication adjustments based on your sensor readings and do not take any other medical action based on your sensor readings without consulting your healthcare provider. Do not use if you have problematic hypoglycemia. Failure to use Stelo and its components according to the instructions for use provided and to properly consider all indications, contraindications, warnings, and cautions in those instructions for use may result in you missing a severe hypoglycemia (low blood glucose) or hyperglycemia (high blood glucose) occurrence. If your sensor readings are not consistent with your symptoms, a blood glucose meter may be an option as needed and consult your healthcare provider. Seek medical advice and attention when appropriate, including before making any medication adjustments and/or for any medical emergency. Patient results may vary.

Endocrinologist Dr. Egils Bogdanovics and Chelsea Lugone join Cher Pastore to break down type 1 diabetes screening and staging: who to screen, how to interpret results, using CGM to prompt action, and current options available to delay progression. Plus practical advice for talking with families and reducing DKA at diagnosis. -- Disclaimer: This podcast is not approved for CME credit. Every diabetes treatment plan is different, individual results may vary – nothing you hear on this podcast should be considered medical advice. All claims are supported by clinical evidence referenced in the show notes. For clinical study results, please refer to the Dexcom G7 User Guide. For product-related questions, please refer to the instructions for use. For complete safety information, go to dexcom.com/safety-information. Fingersticks are required for diabetes treatment decisions if symptoms or expectations do not match readings. Dexcom G7 can complete warmup within 30 minutes, whereas other CGM brands require up to an hour or longer. Smart devices are sold separately. For a list of compatible smart devices, visit: dexcom.com/compatibility. “Dexcom" refers to the Dexcom CGM. Compatible smartphone is required to pair a new Dexcom G7 sensor with a compatible Apple Watch. To use Share/Follow the smartphone must be within 33 feet of the Dexcom G7. The Dexcom G7 Continuous Glucose Monitoring System (Dexcom G7 System) is a real time, continuous glucose monitoring device indicated for the management of diabetes in persons aged 2 years and older. Dexcom G7 has no limitations for use in pregnancy. G7 15 Day is only for adults 18+. This guest is a paid spokesperson for Dexcom. Brief Safety Statement:                                                                                                        Failure to use the Dexcom Continuous Glucose Monitoring System and its components according to the instructions for use provided with your device and available at https://www.dexcom.com/safety-information and to properly consider all indications, contraindications, warnings, precautions, and cautions in those instructions for use may result in you missing a severe hypoglycemia (low blood glucose) or hyperglycemia (high blood glucose) occurrence and/or making a treatment decision that may result in injury. If your glucose alerts and readings from the Dexcom CGM do not match symptoms, use a blood glucose meter to make diabetes treatment decisions. Seek medical advice and attention when appropriate, including for any medical emergency. Dexcom, Dexcom Follow, Dexcom Clarity, and Dexcom Share are registered trademarks of Dexcom, Inc. in the U.S., and may be registered in other countries. STELO IMPORTANT INFORMATION: Consult your healthcare provider before making any medication adjustments based on your sensor readings and do not take any other medical action based on your sensor readings without consulting your healthcare provider. Do not use if you have problematic hypoglycemia. Failure to use Stelo and its components according to the instructions for use provided and to properly consider all indications, contraindications, warnings, and cautions in those instructions for use may result in you missing a severe hypoglycemia (low blood glucose) or hyperglycemia (high blood glucose) occurrence. If your sensor readings are not consistent with your symptoms, a blood glucose meter may be an option as needed and consult your healthcare provider. Seek medical advice and attention when appropriate, including before making any medication adjustments and/or for any medical emergency. Patient results may vary.

How is continuous glucose monitoring (CGM) transforming pregnancy care? In this special episode, maternal-fetal medicine expert Dr. Stacey Ehrenberg and diabetes educator Joy Cornthwaite, RD, join Real-Time Real Talk to break down the latest research from the ADA Conference and share real-world stories of Dexcom G7 in action. Discover how CGM empowers patients and providers, overcomes clinical barriers, and delivers personalized insights for healthier pregnancies and beyond. Listen now: https://provider.dexcom.com/education-research/podcast   Disclaimer: This podcast is not approved for CME credit. Every diabetes treatment plan is different, individual results may vary – nothing you hear on this podcast should be considered medical advice. All claims are supported by clinical evidence referenced in the show notes. For clinical study results, please refer to the Dexcom G7 User Guide. For product-related questions, please refer to the instructions for use. For complete safety information, go to dexcom.com/safety-information.  Fingersticks required for diabetes treatment decisions if symptoms or expectations do not match readings. Dexcom G7 can complete warmup within 30 minutes, whereas other CGM brands require up to an hour or longer. Smart devices are sold separately. For a list of compatible smart devices, visit: dexcom.com/compatibility. “Dexcom" refers to the Dexcom CGM. Compatible smartphone is required to pair a new Dexcom G7 sensor with a compatible Apple Watch. To use Share/Follow the smartphone must be within 33 feet of the Dexcom G7. The Dexcom G7 Continuous Glucose Monitoring System (Dexcom G7 System) is a real time, continuous glucose monitoring device indicated for the management of diabetes in persons aged 2 years and older. Dexcom G7 has no limitations for use in pregnancy. G7 15 Day is only for adults 18+. This guest is a paid spokesperson for Dexcom. Brief Safety Statement:        Failure to use the Dexcom Continuous Glucose Monitoring System and its components according to the instructions for use provided with your device and available at https://www.dexcom.com/safety-information and to properly consider all indications, contraindications, warnings, precautions, and cautions in those instructions for use may result in you missing a severe hypoglycemia (low blood glucose) or hyperglycemia (high blood glucose) occurrence and/or making a treatment decision that may result in injury. If your glucose alerts and readings from the Dexcom CGM do not match symptoms, use a blood glucose meter to make diabetes treatment decisions. Seek medical advice and attention when appropriate, including for any medical emergency. Dexcom, Dexcom Follow, Dexcom Clarity, and Dexcom Share are registered trademarks of Dexcom, Inc. in the U.S., and may be registered in other countries. STELO IMPORTANT INFORMATION: Consult your healthcare provider before making any medication adjustments based on your sensor readings and do not take any other medical action based on your sensor readings without consulting your healthcare provider. Do not use if you have problematic hypoglycemia. Failure to use Stelo and its components according to the instructions for use provided and to properly consider all indications, contraindications, warnings, and cautions in those instructions for use may result in you missing a severe hypoglycemia (low blood glucose) or hyperglycemia (high blood glucose) occurrence. If your sensor readings are not consistent with your symptoms, a blood glucose meter may be an option as needed and consult your healthcare provider. Seek medical advice and attention when appropriate, including before making any medication adjustments and/or for any medical emergency. Patient results may vary.

Only 1 in 5 people with type 2 diabetes on insulin use Continuous Glucose Monitoring (CGM) and for those not on insulin, that number drops to just 5%. With real-time glucose tracking transforming how patients understand and manage their health, why isn’t CGM more widely used? In this live episode from the American Diabetes Association (ADA) Conference, Real-Time Real Talk explores the barriers, breakthroughs, and future of diabetes technology. You'll hear why CGM is gaining traction not just for type 1 diabetes, but also in primary care, prediabetes, and even among the glucose-curious. -- Disclaimer: This podcast is not approved for CME credit. Every diabetes treatment plan is different, individual results may vary – nothing you hear on this podcast should be considered medical advice. All claims are supported by clinical evidence referenced in the show notes. For clinical study results, please refer to the Dexcom G7 User Guide. For product-related questions, please refer to the instructions for use. For complete safety information, go to dexcom.com/safety-information. Fingersticks required for diabetes treatment decisions if symptoms or expectations do not match readings. Dexcom G7 can complete warmup within 30 minutes, whereas other CGM brands require up to an hour or longer. Smart devices are sold separately. For a list of compatible smart devices, visit: dexcom.com/compatibility. “Dexcom" refers to the Dexcom CGM. Compatible smartphone is required to pair a new Dexcom G7 sensor with a compatible Apple Watch. To use Share/Follow the smartphone must be within 33 feet of the Dexcom G7. The Dexcom G7 Continuous Glucose Monitoring System (Dexcom G7 System) is a real time, continuous glucose monitoring device indicated for the management of diabetes in persons aged 2 years and older. Dexcom G7 has no limitations for use in pregnancy. G7 15 Day is only for adults 18+. This guest is a paid spokesperson for Dexcom. Brief Safety Statement:                                                                                                        Failure to use the Dexcom Continuous Glucose Monitoring System and its components according to the instructions for use provided with your device and available at https://www.dexcom.com/safety-information and to properly consider all indications, contraindications, warnings, precautions, and cautions in those instructions for use may result in you missing a severe hypoglycemia (low blood glucose) or hyperglycemia (high blood glucose) occurrence and/or making a treatment decision that may result in injury. If your glucose alerts and readings from the Dexcom CGM do not match symptoms, use a blood glucose meter to make diabetes treatment decisions. Seek medical advice and attention when appropriate, including for any medical emergency. Dexcom, Dexcom Follow, Dexcom Clarity, and Dexcom Share are registered trademarks of Dexcom, Inc. in the U.S., and may be registered in other countries. STELO IMPORTANT INFORMATION: Consult your healthcare provider before making any medication adjustments based on your sensor readings and do not take any other medical action based on your sensor readings without consulting your healthcare provider. Do not use if you have problematic hypoglycemia. Failure to use Stelo and its components according to the instructions for use provided and to properly consider all indications, contraindications, warnings, and cautions in those instructions for use may result in you missing a severe hypoglycemia (low blood glucose) or hyperglycemia (high blood glucose) occurrence. If your sensor readings are not consistent with your symptoms, a blood glucose meter may be an option as needed and consult your healthcare provider. Seek medical advice and attention when appropriate, including before making any medication adjustments and/or for any medical emergency. Patient results may vary.
 MAT-9989

Lance Bass discusses an honest look at misdiagnosis, diabetes stigma, and how real-time Continuous Glucose Monitoring (CGM) transformed his life on this special episode of Real-Time Real Talk recorded live at the American Diabetes Association conference (ADA) in Chicago this June. When Lance was first diagnosed with type 2 diabetes, it didn’t make sense - he ate well, exercised, and didn’t fit the typical profile. But as his glucose remained high and symptoms worsened, he discovered he actually had LADA (Latent Autoimmune Diabetes in Adults), a slow-progressing form of type 1 diabetes. Host Cher Pastore, MS, RD, CDCES, BC-ADM sits down with Lance to unpack his journey from misdiagnosis to managing his condition with CGM and advanced diabetes technology. Lance shares how CGM with the Dexcom G7 transformed his diabetes management, allowing him to see blood sugar levels in real time, avoid dangerous lows, and personalize his food and insulin decisions. They discuss everything from automated insulin delivery systems to blood sugar monitoring tips, glucose sensors, and the mental relief that comes from not having to guess what’s happening in your body. He also opens up about raising awareness, reducing stigma for young people with diabetes, and why showing his G7 publicly has helped others feel seen and supported. Whether you're a healthcare provider, parent, or person living with diabetes, this episode offers powerful insight into the life-changing potential of CGM technology and is a must-listen for anyone affected by type 1 diabetes, type 2 diabetes, or prediabetes - including patients, endocrinologists, and primary care providers. The interview offers an honest and insightful look at how biosensor tools like CGM are reshaping diabetes treatment, diabetes education, and metabolic health outcomes.